Today: 17 May 2026
Browse Category

QSE:QIBK 15 February 2026 - 1 March 2026

Stock Market Today

  • Bill Ackman Reveals $2.09 Billion Stake in Major Tech Stock
    May 17, 2026, 4:44 AM EDT. Billionaire investor Bill Ackman disclosed a $2.09 billion stake in a megacap technology company, which he began acquiring quietly in February. Ackman revealed his rationale behind the purchase, signaling confidence in the tech sector's potential. This strategic move by Ackman underscores his continued interest in high-value tech stocks amid fluctuating market conditions.

Latest articles

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 17.05.2026

17 May 2026
LIVEMarkets rolling coverageStarted: May 17, 2026, 4:00 AM EDTUpdated: May 17, 2026, 4:52 AM EDT Bill Ackman Reveals $2.09 Billion Stake in Major Tech Stock May 17, 2026, 4:44 AM EDT. Billionaire investor Bill Ackman disclosed a $2.09 billion stake in a megacap technology company, which he began acquiring quietly in February. Ackman revealed his rationale behind the purchase, signaling confidence in the tech sector’s potential. This strategic move by Ackman underscores his continued interest in high-value tech stocks amid fluctuating market conditions. Bill Ackman discloses new $2.09 billion stake in megacap tech stock Kromek Penny Stock Set to Soar
Joby Aviation Slides Monday With Air-Taxi in Focus

Joby Aviation Slides Monday With Air-Taxi in Focus

17 May 2026
Joby Aviation shares closed Friday at $10.36, down 2.6% for the day and 4.7% for the week. CEO JoeBen Bevirt-linked trusts sold over 421,000 shares under a preset 10b5-1 plan, filings showed. The stock traded between $10.04 and $10.58 during a volatile week. Broader markets and eVTOL sector peers also declined.
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

17 May 2026
ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities.
Infleqtion Shares Slide After Record Revenue, Market Looks to Next INFQ Catalyst

Infleqtion Shares Slide After Record Revenue, Market Looks to Next INFQ Catalyst

17 May 2026
Infleqtion Inc. shares fell 10.95% to $12.44 Friday, capping a rough week for quantum tech stocks. The company reported a first-quarter net loss of $30.3 million on $9.5 million in revenue, with 85% from government contracts. Infleqtion launched a new RF sensing platform and raised its 2026 revenue outlook, but warned of continued operating losses.
Go toTop